CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?

By M. Zöller. Nature Reviews. Cancer, 2011

1,163 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The biology and role of CD44 in cancer progression: therapeutic implications (2018, background): “HA binds the CD44 ligand binding domain inducing conformational changes that allow binding of adaptor proteins or cytoskeletal elements to intracellular domains that in turn activate various signaling pathways leading to cell proliferation, adhesion, migration, and invasion [7, 8].”
Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer (2015, background): “More importantly, variants of CD44, specifically CD44v6, promote tumor progression and metastatic potential in lung, breast, and colon cancer (6, 24, 94, 95, 148, 149).”
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma (2013, background): “, 2011), a marker that is enriched in cancer stem cells as well as those that undergo epithelial to MES transition (EMT; Zöller, 2011).”